तुलना करने के लिए मीट्रिक्स | PHAR | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधPHARपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 37.0x | −1.5x | −0.2x | |
PEG अनुपात | 0.00 | 0.02 | 0.00 | |
क़ीमत/बुक | 3.1x | 1.8x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 2.3x | 4.1x | 2.7x | |
अपसाइड (विश्लेषक लक्ष्य) | 98.0% | 95.2% | 66.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 9.8% | 10.8% | अनलॉक करें |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.